Gastric Cancer

Current Problems in Surgery

Volumn 34, Issue 11, 1997, Pages 846-939

  Siewert, J R ^a   Fink, U ^a   Sendler, A ^a   Becker, K ^a   Bottcher K ^a   Feldmann, H J ^a   Hofler H ^a   Mueller, J ^a   Molls, M ^a   Nekarda, H ^a   Roder, J D ^a   Stein, H J ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER STAGING; CARCINOMA; GASTRECTOMY; HUMAN; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; REVIEW; STOMACH TUMOR;

ANTINEOPLASTIC AGENTS; CARCINOMA; COMBINED MODALITY THERAPY; GASTRECTOMY; HUMANS; NEOPLASM STAGING; PALLIATIVE CARE; STOMACH NEOPLASMS;

EID: 0031264308     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-3840(97)80006-8     Document Type: Article

References (217)

1. Antonioli DA, Goldman H. Changes in the location and type of gastric adenocarcinoma. Cancer 1982:50:775-81.
2. Kampschöer GHM, Nakajima T, van de Velde CJH. Changing patterns in gastric adenocarcinoma. Br J Surg 1989:76:914-6.
3. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
4. Zheng T, Taylor Mayne S, Holford TR, et al. The time trend and age-period-cohort effects on incidence of adenocarcinoma of the stomach in Connecticut from 19551989. Cancer 1993:72:330-40.
5. Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161:626-33.
6. Tally NJ, Zinsmeister AR, Weaver A, et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst 1991:83:1734-9.
7. Parsonnet J, Fridman GD, Vandersteen DP. et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991 ;325:1127-31.
8. Forman D. Helicobacter pylori infection: a novel risk factor in the etiology of gastric cancer. J Natl Cancer Inst 1991:83:1702-3.
9. Wang HH, Antonioli DA, Goldman H. Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. Hum Pathol 1986:17:482-7.
10. Yang PC, Davis S. Epidemiological characteristics of adenocarcinoma of the gastric cardia and distal stomach in the United States, 1973-1982. Int J Epidemiol 1988:17:293-7.
11. Laurén, P. The two histologie main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965:64:31-49.
12. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990;62:440-3.
13. Zheng T, Mayne ST, Holford T, et al. The time trend, and age-period-cohort effects on incidence of esophageal cancer in Connecticut. Cancer Causes Control 1992;3:481-92.
14. MacDonald WC, MacDonald JB. Adenocarcinoma of the esophagus and/or gastric cardia. Cancer 1987:60:1094-8.
15. Golematis B, Tzardis P, Hatzikostas P, Papadimitriou K, Haritopoulos N. Changing patterns of distribution of carcinoma of the stomach. Br J Surg 1990:77:63-4.
16. Husemann B. Cardia carcinoma considered as a distinct clinical entity. Br J Surg 1989:76:136-9.
17. Craanen ME, Dekker W. Blok P, Ferwerda J, Tytgat GNJ. Time trends in gastric carcinoma: changing patterns of type and location. Am J Gastroenterol 1992;87:572-9.
18. Rakic S, Milicevic MN, Kovacevic P, Markovic V. Increasing incidence of adenocarcinoma of the proximal stomach. Eur J Surg Oncol 1992; 18:340-1.
19. Wanebo H, Kennedy B, Chimiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993:218:538-92.
20. Mikulin T, Hardcastle J. Gastric cancer: delay and its causes. Eur J Cancer 1987:23:1683-90.
21. Zilling T, Walther B, Ähren B. Delay in diagnosis of gastric cancer: A prospective study evaluating doctors' and patients' delay and its influence on five year survival. Anticancer Res 1990; 10:411 -6.
22. Scotcher S, Sikora K, Freedmann L. Gastric cancer and cimetidine: does delay in diagnosis matter? Lancet 1981;2:630-1.
23. Hackett T, Cassem NH, Raker J. Patient delay in cancer. N Engl J Med 1973;27:14-20.
24. Gray D, Grant E. Delay in diagnosis of carcinoma of the stomach. Am J Surg 1952:57:524-6.
25. Wile A, Hourani L, Schell M. The contributions of patient factors, physician delay and tumor biology on the outcome of gastric cancer. Am Surg 1993:59:850-4.
26. Haugvstedt T, Viste A, Eide E, Soreide O. Patient and physician treatment delay in patients with stomach cancer in Norway: is it important? Scand J Gastroenterol 1991:26:611-9.
27. Delay in diagnosing and treating cancer (review article). Oncology in Practice; 92: 6-13 (part 1) and 93: 4-10 (part 2).
28. Jenkins S. Diagnostic delay in neoplastic disease. J R Coll Gen Pract 1978;28:724-8.
29. Lim BS. Dennis CR, Gardner B. Analysis of survival versus patient and doctor delay in gastrointestinal cancer. Am J Surg 1974;127:210-4.
30. Hallissey M, Allum W, Jewkes A, Fielding J. Early detection of gastric cancer. Br MedJ 1990:301:513-5.
31. Schönberger B, Fink U, Busch R, Herrschbach P, Siewert JR. Die prätherapeutische Phase bei Patienten mit Magencarcinom - Evaluation der einflufaktoren. Thesis 1995.
32. Stoddard C. Smith J, Johnson A. Cimetidine, delay in diagnosis and carcinoma of the stomach (Letter to the Editor). Lancet 1980:2:199-200.
33. Roder JD, Böttcher K, Siewert JR, et al. Prognostic factors in gastric carcinoma. Cancer 1993;72:2089-97.
34. Kinoshita T, Maruyama K, Sasako M, Okajima K. Treatment results of gastric cancer patients: Japanese experience. In: Nishi M, Ichikawa H, Nakajinia T, Maruyama K. Tahara E (Hrsg), editors. Gastric cancer. Tokyo: Springer Verlag; 1993. p. 319-30.
35. Gabbert HE, Müller W. Prospective prognostic factors in gastric cancer. In: Roher HD, Heise JW, Verreet PR, Varney (Hrsg), editors. Update in gastric surgery. Stuttgart: Georg Thieme; 1994. p. 76-82.
36. Hermanek P, Sobin LH. UICC TNM classification of malignant tumours. 4th ed. 2nd rev. Berlin: Springer; 1992.
37. Beahrs OH, Henson DE, Hutter RVP. Kennedy BJ. Manual for staging of cancer. 4th ed. Philadelphia: Lippincott; 1992.
38. Hermanek P, Henson DE, Hutter RUP, Sobin LH. UICC TNM supplement. A commentary on uniform use. Berlin: Springer: 1993.
39. Siewert JR, Kestlmeier R, Busch R, et al. Benefits of D2 lymph node dissection for patients with gastric cancer and pNO and pNl lymph node métastases. Br J Surg 1996;83:1144-7.
40. Rohde H, Bauer R Stützer H, Heitmann K, Gebbensleben B. Proximal compared with distal adenocarcinoma of the stomach: differences and consequences. Br J Surg 1991:78:1242-8.
41. Nakane Y, Okamura S, Boku T, Okusa T, Tanaka K, Hiolci K. Prognostic differences of adenocarcinoma arising from the cardia and the upper third of the stomach. Am Surg 1993;59:423-9.
42. Siewert JR, Böttcher K, Stein HJ, Roder JD, Busch R. Problem of proximal third gastric carcinoma. World J Surg 1995; 19:523-31.
43. Domellöf L. Remnant stomach and gastric cancer. In: Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, editors. Gastric cancer. Berlin: Springer; 1993 p. 168-82.
44. Watanabe H, Jass JR, Sobin LH. Histological typing of oesophageal and gastric tumours. 2nd ed. WHO International Histological Classification of Tumours. Berlin: Springer; 1990.
45. Matsui K, Kitagawa M, Miwa A, Kuroda Y, Tsuji M. Small cell carcinoma of the stomach: a clinico-pathologic study of 17 cases. Am J Gastroenterol 1991;86:116775.
46. Böttcher K, Becker K, Busch R, Roder JD, Siewert JR. Prognosefaktoren beim Magencarcinom. Ergebnisse einer uni- und multivariaten Analyse. Chirurg 1992;63:656-61.
47. Gabbert HE, Meier S, Gerharz CD, Hommel G. Tumor-cell dissociation at the invasive front: a new prognostic parameter in gastric cancer patients. Int J Cancer 1991;50:202-7.
48. Rugge M, Sonego F, Panozzo M, et al. Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis. Cancer 1993;73:1127-33.
49. Ohyama S, Yonemura Y, Miyazaki I. Proliferative activity and malignancy in human gastric cancers: significance of the proliferation rate and its clinical application. Cancer 1992;69:314-21.
50. Maehara Y, Kusumoto T, Takahashi I, et al. Predictive value of preoperative carcinoembryonic antigen levels for the prognosis of patients with well-differentiated gastric cancer. Oncology 1994;51:859-62.
51. Onorato A, Ohkura H, Okajima K, Sasako M, Kinoshita T, Maruyama K. Nonanatomic prognostic factors for gastric cancer patients: significance of tumor markers. In: Takahashi T, editor. Recent advances in management of digestive cancers. Berlin: Springer; 1993.
52. Boku T, Nakane Y, Minoura T, et al. Prognostic significance of serosal invasion and free intraperitoneal cancer cells. Br J Surg 1993;77:436-41.
53. Kaibara N, litsuka Y, Kimura A, et al. Relationship between area of serosal invasion and prognosis in patients with gastric cancer. Cancer 1987;60:136-9.
54. Bonenkamp JJ, Songun I, Hermans J, van de Velde CJH. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 1996:83:672-4.
55. Nekarda H, Schenck U, Ludwig C, et al. Prognosis of free abdominal cancer cells in totally resected gastric cancer [Abstract]. Eur J Surg Oncol 1994;20:361.
56. Asao T, Fukuda T, Yazawa S, Nagamachi Y. Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer. Cancer 1991;68:44-7.
57. Riethmiiller G, Johnson JP. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Op Immunol 1992;4:647-55.
58. Heiss MM, Allgayer H, Grützner KU, et al. Individual development and uPA receptor expression of disseminated tumor cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med 1995;l:1035-9.
59. Tamura G, Kihana T, Nomura K, Sunicha U. Detection of frequent p53 mutations in primary gastric cancer by cell sorting and polymerase chain reaction single strand conformation analysis. Cancer Res 1991;51:3056-8.
60. Martin HM, Filipe MI, Morris RW. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859-62.
61. Anin MB, Ma CK, Linden MD, Kubus JJ, Zarbo RJ. Prognostic value of proliferating cell nuclear antigen index in gastric stromal tumors. Am J Clin Pathol 1993:100:428-32.
62. Begg AC, McNally NJ, Shrieve DC, Kärcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985;6:620-6.
63. Kamata T, Yonemura Y, Sugiyama K, et al. Proliferative activity of early gastric cancer measured by in vitro and in vivo bromodeoxyuridine labeling. Cancer 1989;64:1665-8.
64. Wilson GD. Assessment of human tumour proliferation using bromodeoxyuridine: current status. Acta Oncol 1991;30:903-10.
65. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-7.
66. Nekarda H, Siewert JR, Schmitt M, Ulm K. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer [Abstract]. Lancet 1994;343:117.
67. Heiss MM, Babic R, Allgayer H, et al. Tumor associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995-,13:2084-93.
68. Korenaga D, Haraguchi M, OkamuraT, Baba H, Saito A, Sugimachi K. DNAploidy and tumor invasion in human gastric cancer. Arch Surg 1989;14:314-8.
69. Parley DR, Donohue JH, Nagomey DM, Carpenter HA, Katzmann JA, Ilstrup DM. Early gastric cancer. Br J Surg 1992;79:539-42.
70. Böttcher K, Siewert JR, Roder JD, et al. Risiko der chiurgischen Therapie des Magencarcinoms in Deutschland. Chirurg 1994;65:298-306.
71. Heberer G, Teichmann RK, Krämling H-J, Günther B. Results of gastric resection for carcinoma of the stomach: the European experience. World J Surg 1988;12:37481.
72. Siewert JR, Böttcher K, Roder JD, et al. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br J Surg 1993;80:1015-8.
73. Maruyama K, Sasako M, Kinoshita T, Okajima K. Effectiveness of systematic lymph node dissection in gastric cancer surgery. In: Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, editors. Gastric cancer. Berlin: Springer; 1993 p. 293305.
74. Keller E, Stützer H, Heitmann K, et al. Lymph node staging in 872 patients with car-cinoma of the stomach and the presumed benefit of lymphadenectomy. J Am Coll Surg 1994; 178:38-46.
75. Maruyama K. The most important prognostic factors for gastric cancer patients: a study using univariate and multivariate analyses. Scand J Gastroenterol 1987:22(Suppl 133):63-8.
76. Moriguchi S, Maehara Y, Akazawa K, Sugimachi K, Nose Y. Lack of relationship between perioperative blood transfusion and survival time after curative resection for gastric cancer. Cancer 1990:66:2331-5.
77. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-8.
78. Bonenkamp JJ, Songun I, Hermans J. et al. Randomized comparison of morbidity after Dl- and D2-dissection for gastric cancer in 996 Dutch patients. Lancet 1995:345:745-8.
79. Kampschoer GH, Maruyama K, Sasako M, Kinoshita T, van de Velde CJH. The effect of blood transfusion on the prognosis of patients with gastric cancer. World J Surg 1989:13:637-43.
80. Hermans J. Bonenkamp JJ, Boon MC. et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;ll:1441-7.
81. Kyoto Research Group for Digestive Organ Surgery. A comprehensive multi-institutional study on postoperative adjuvant immonotherapy with oral streptococcal preparation OK-432 for patients after gastric cancer surgery. Ann Surg 1992;216:4454.
82. Abe M, Takahashi M. Intraoperative radiotherapy: the Japanese experience. Int J Radiât Oncol Biol Phys 1981;13:1821-7.
83. Kim J-P. The concept of immunochemosurgery in gastric cancer. World J Surg 1987; 1:465-72.
84. Fink U. Schuhmacher Ch, Stein HJ, et al. Preoperative chemotherapy for stage IIIIV gastric carcinoma: feasibility, response and outcome after complete resection. Br JSurg 1995;82:1248-52.
85. Japanese Research Committee for Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Jpn J Surg 1981;! 1:127-38.
86. Sendler A, Dittler HJ. Feuner H, et al. Preoperative staging of gastric cancer as precondition for multimodal treatment. World J Surg 1995; 19:501-8.
87. Rösch Th. Endosonographic staging of gastric cancer: a review of literature results. Gastrointestinal Clinics of North America 1995:3:549-57.
88. Abe S, Lightdale CJ. Brennan MR The Japanese experience with endoscopie ultrasonography in the staging of gastric cancer. Gastrointest Endosc 1993:39:586-91.
89. Rösch T, Classen M. Gastroenterologic endosonography. Stuttgart: Georg Thieme; 1992.
90. Rösch T, Lorenz R, Zenker K et al. Local staging and assessment of resectability in carcinoma of the esophagus, stomach and duodenum by endoscopie ultrasonography. Gastrointest Endosc 1992;38:460-7.
91. Dittler HJ, Siewert JR. Role of endoscopie ultrasonography in gastric carcinoma. Endoscopy 1993 ;25:162-6.
92. Maehara Y, Moriguchi S, Orita H, et al. Lower survial rate for patients with carcinoma of the stomach of Borrmann type IV after gastric resection. Surg Gynecol Obstet 1992:175:13-6.
93. Botet JF, Lightdale CJA, Zauber AG, et al. Preoperative staging of gastric cancer: comparison of endoscopie US and dynamic CT. Radiology 1991;181:426-32.
94. Ziegler K, Sanft C, Zimmer T, et al. Comparision of computed tomography, endosonography and intraoperative assessment in TN staging of gastric carcinoma. Gut 1993;34:604-10.
95. Grimm H, Hamper K, Maydeo A, et al. Accuracy of endoscopie ultrasound and computed tomography in determining of local/regional spread of gastric cancer: results of a prospective controlled study. Gastrointest Endosc 1991 ;37:279.
96. Lightdale CJ. Endoscopie ultrasonography in the diagnosis, staging and follow-up of esophageal and gastric cancer. Endoscopy 1992;25(Suppl):297-303.
97. Maruyama K, Gunvén P, Okabayashi K, et al. Lymph node métastases in gastric cancer. Ann Surg 1989;210:596-601.
98. Cho J-S, Kim J-K, Rhô S-M, et al. Preoperative assessment of gastric carcinoma: value of two-phase dynamic CT with mechanical IV infusion of contrast material. AJR Am J Roentgenol 1994;163:69-75.
99. Dupont JB, Lee JR, Burton GR, Cohn I. Adenocarcinoma of the stomach: review of 1497 cases. Cancer 1978;41:941-7.
100. Weiss M, Eder M, Bassermann R. Charakterisierung verschiedener magenkarzinomtypen mit unterschiedlicher metastasierung in leber, peritoneum und knochen. Pathologie 1993;14:260-4.
101. Heiken JP, Weyman PJ, Lee IL, et al. Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989; 171:47-51.
102. Soyer P, Levesque M, Caudron C, et al. MRI of liver métastases from colorectal cancer vs CT during portography. J Comput Assist Tomogr 1993;17:67-71.
103. Zocholl G, Kühn FP, Augustin N. Diagnostische aussagekraft von sonographie und Computertomographie bei lebermetastasen. ROFO Fortschr Geb Rontgenstr Nuklearmed 1988;148:8-14.
104. Kriplani AK, Kapur ML. Laparoscopy for pre-operative staging and assessment of operability in gastric carcinoma. Gastrointest Endosc 1991;37:441-3.
105. Possik RA, Franco EL, Pires ER, et al. Sensitivity, specificity, and predictive value of laparoscopy for the staging of gastric cancer and for the detection of liver métastases. Cancer 1986;58:l-6.
106. Feuner H, Fink U, Walker SJ, et al. Preoperative laparoscopic staging in advanced gastric carcinoma. In: Nishi M, Sugano H, Takahashi T, editors. First International Gastric Cancer Congress, Kyoto, 1995. Bologna, Italy: Monduzzi; 1995. p. 83-7,
107. Molloy RG, McCourtney JS, Anderson JR. Laparoscopy in the management of patients with cancer of the gastric cardia and oesophagus. Br J Surg 1995;82: 352-4.
108. Laccourreye O, Chabardes E, Merite-Drancy A, et al. Implantation metastasis following percutaneous endoscopie gastrostomy. J Laryngol Otol 1993;107:946-9.
109. Bollschweiler E, Böttcher K, Kölscher AH, et al. Preoperative assessment of lymph node métastases in patients with gastric cancer: evaluation of the Maruyama computer program. Br J Surg 1992;79:156-60.
110. Bollschweiler E, Böttcher K, Kölscher AH, et al. Is the prognosis for Japanese patients with gastric cancer really different? Cancer 1993;71:2918-25.
111. Siewert JR, Kölscher AH, Becker K, Gössner W. Kardiakarzinom: Versuch einer therapeutisch relevanten klassifikation. Chirurg 1987;58:25-32.
112. Fink U, Stein HJ, Schuhmacher C, Wilke HJ. Neo-adjuvant chemotherapy: an update. World J Surg 1995;19:509-16.
113. Hüd Y, Sakakibara Y, Mieno H, Shirnao H, Kobayashi N, Katada N. Endoscopie treatment of gastric cancer. Surg Endosc 1991;5:ll-3.
114. Ohgami M, Kumai K, Wakabayashi G, Otani Y, Katajima M. Innovative treatment for early gastric cancer, laparoscopic wedge resection of the stomach using the lesion-lifting method (in Japanese). Stomach and Intestine 1993;28:1461-8.
115. Shiu MH, Moore E, Sanders M, et al. Influence of the extent of resection on survival after curative treatment of gastric carcinoma: a retrospective multivariate analysis. Arch Surg 1987; 122:1347-52.
116. Jaehne J, Meyer HJ. Maschek H, Geerlings H, Bruns E, Pichhnayr R. Lymphadenectomy in gastric carcinoma: a prospective and prognostic study. Arch Surg 1992; 127:290-4.
117. Maruyama K, Guvén P, Okabayashi K, Sasako M, Kinoshita T. Lymph node métastases of gastric cancer: general pattern in 1931 patients. Ann Surg 1989;210:596-602.
118. Maruyama K. A new dissection technique of superior pancreatic lymph nodes, pancreas preserving radical gastrectomy. Japanese Journal of Gastroenterological Surgery 1979; 12:961-70.
119. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radically. World J Surg 1987; 11:418-25.
120. Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopie resection of tumour. Br J Surg 1992:79:241-4.
121. Yasuda K, Mizuma Y, Nakajima M, Kawai K. Endoscopie laser treatment for early gastric cancer. Endoscopy !993;25:451-4.
122. Tada M, Murakami A, Karita M, Yanai H, Okita K. Endoscopie resection of early gastric cancer. Endoscopy 1993;25:445-50.
123. Roder JD, Herschbach P, Sellschopp A, Siewert JR. Quality-of-life assessment following oesophagectomy. Theoretical Surgery 1991;6:206-10.
124. Siewert JR, Böttcher K. Ösophagojejunoplikatio in Stapler-Technik. Ergebnisse einer kontrollierten Studie. Langenbecks Arch Chir 1992;377:186-9.
125. Siewert JR, Schattenmann G. Esophagojejunoplication. In: Herfarth C, Schlag P, editors. Gastric cancer. Berlin: Springer; 1979. p. 272-9.
126. Herfarth Ch, Schlag P, Buhl K. Surgical procedures for gastric substitution. World J Surg 1987; 11:689-98.
127. van de Velde CJH. Oral communication with J.R. Siewert, April 1997.
128. Fink U, Schuhmacher C, Böttcher K, et al. Neoadjuvant chemotherapy with etoposide/adriamycin and cisplatine in locally advanced gastric carcinoma. In: Salmon SE, editor. Adjuvant therapy of cancer. Philadelphia: JB Lippincott; 1993. p. 272-80.
129. Shiu MH, Perrotti M, Brennan MF. Adenocarcinoma of the stomach: a multivariate analysis of clinical, pathologic and treatment factors. Hepatogastroenterol 1989;36:7-12.
130. Sarrazin R, Pissas A, Dyon JF, Bouchet Y. Lymphatic drainage of the stomach. Anat Clin 1980;2:95-110.
131. Schmitz-Morrmann P, Pohl C, Himmelmann G, Neumann K. Morphologic predictors of survival in patients in advanced gastric carcinoma: univariate and multivariate analysis. J Cancer Res Clin One 1986; 112:156-64.
132. Hermanek P, Gospodarowicz M, Henson D, Hutter R, Sobin L. Prognostic factors in cancer. 1st ed. Berlin: Springer; 1995. p. 290-304.
133. Ming S-C. Gastric carcinoma: a pathobiological classification. Cancer 1977; 39:2475-85.
134. Moutinho-Ribeiro M, Seixas M, Sobrinho-Simoes M. Prognosis in gastric carcinoma: the preeminence of staging and the futility of histological classification. In: Watanabe S, Wolff M, Sommers S, editors. Vol 1. Digestive disease pathology. Berlin: Springer; 1988; p. 5168-81.
135. Böttcher K, Roder J, Busch R, et al. Epidemiologie des Magenkarzinoms aus chrirurgischer sieht - Ergebnisse der Deutschen Magen-Karzinom Studie 1992. Dtsch Med Wochenschr 1993;118:729-36.
136. Siewert JR, Böttcher K, Bollschweiler E. TNM-Klassifikation bei Magenkarzinomdas Problem der T2-Tumoren. Dtsch Med Wochenschr 1991 ; 116:473-5.
137. Wagner P, Ramaswamy A, Rüschoff J, Schmitz-Moormann P, Rothmund M. Lymph node counts in the upper abdomen: anatomical basis for lymphadenectomy in gastric cancer. Br J Surg 1991;78:825-7.
138. Hermanek P. pTNM and residual tumor classifications: Problems of assessment and prognostic significance. World J Surg 1995; 19:184-90.
139. Okusa T, Nakane Y, Boku T, et al. Quantitative analysis of nodal involvement with respect to survival rate after curative gastrectomy for carcinoma. Surgery 1990; 170:488-94.
140. Werner M, Nasarek A, Georgil A. Isolated tumor cells in the bone marrow: value of a new diagnostic method in the TNM-staging of solid tumors. Gen Diagn Pathol 1996:142:1-6.
141. Maruyama K. Diagnosis of invisible peritoneal métastases: cytologie examination by peritoneal lavage. In: Cordiano C, de Manzoni G, editors. Staging and treatment of gastric cancer. Radua: Piccin Nuova Libraria; 1991 p. 117-23.
142. Misiewicz J, Tydgat G, Goodwin C, et al. The Sydney system: a new classification of gastritis. World Congress of Gastroenterology. Melbourne: Blackwell; 1990. p. 110.
143. Borrmann R. Geschwülste des Magens und Duodénums. In: Henke F, Lubarsch O. Handbuch der speziellen pathologischen Anatomie und Histologie. Vol 4. Berlin: Springer; 1926. p. 865-79.
144. Leach SD, Lowy AM, Mansfield PF, Ajani JA. Adjuvant therapy for resectable gastric adenocarcinotna: preoperative and postoperative chemotherapy trials. J Infus Chemoth 1995;5:104-11.
145. Hermans J, Bonenkamp JJ, Boon AMG, et al. Adjuvant therapy after curative resection for gastric cancer. J Clin Oncol 1993;ll:1441-7.
146. Hermans J, Bonenkamp H. Letter to the Editor. J Clin Oncol 1993; 12:879-80.
147. Douglass HO Jr. Adjuvant therapy of gastric cancer: Have we made any progress? Ann Oncol 1994;5:49-57.
148. Nakajima T. Review of adjuvant chemotherapy for gastric cancer. World J Surg 1995:19:570-4.
149. Fink U, Stein HJ, Schuhmacher C, Wilke HJ. Neoadjuvant therapy for gastric cancer: update. World J Surg 1995; 19:509-16.
150. Hallissey MT, Dünn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer. Lancet 1994;343:1309-12.
151. Lise M, Nitti D, Marchet A, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin and mitomycin regimen in resectable gastric cancer. J Clin Oncol 1995:13:2757-63.
152. Rougier Ph, Lasser Ph, Ducreux M, Mahjoubi M, Bognel C. Elias D. Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 1994;5:S59-S68.
153. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979:39:3861-7.
154. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of métastases. Cancer Res 1983:43:1488-92.
155. Goldie JH, Coldman AJ. A mathematical model for relating drug sensitivity of tumors and their spontaneous mutation rate. Cancer Treat Rep 1979:63:1727-30.
156. Stephens FO. Adams BG, Créa P. Intra-arterial chemotherapy given preoperatively in the management of carcinoma of the stomach. Surg Gynecol Obstet 1986; 162:370-4.
157. Fujimoto S, Akao T, Itoh B. A study of survival in patients with stomach cancer treated by a combination of preoperative intraarterial infusion therapy and surgery. Cancer 1976:37:1648-53.
158. Bonatsos C, Aust J, Meisner D, Poisez B, Comis R. Preoperative chemotherapy for patients with locally advanced gastric carcinoma [Abstract]. Proceedings of the American Society of Clinical Oncology 1985:4:83.
159. Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer, J. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide. doxorubicin and cisplatin. J Clin Oncol 1989:7:1318-26.
160. Plukker JT, Mulder NH. Sleijfer DTH, Grond J, Verschueren RJC. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991;78:955-8.
161. Rosen HR, Scheithauer W, Jakesz R, et al. Epirubicin, etoposide and cisplatin in the treatment of locally advanced, nonresectable gastric carcinoma: results of a multicentric pilot study. Gastro-Intestinal Cancer 1995:1:49-53.
162. Facchini G, Tortoriello A, Caponigro F. et al. Neoadjuvant chemotherapy in locally advanced gastric cancer: preliminary results of a phase II trial with modified FAMTX combination. Oncol Rep 1995:2:727-30.
163. Ajani JM, Ota DM, Jessup M, Ames FC, McBride C. Boddie A. Resectable gastriccarcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer 1991:68:1501-6.
164. Ajani JM, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M. Preoperative and postoperative chemotherapy for patients with potentially resectable gastric carcinoma. J Natl Cancer Inst 1993:85:1839-44.
165. Leichman L, Silberman H, Keichman CG, et al. Intravenous neoadjuvant chemotherapy for operable gastric cancer patients followed by intraperitoneal therapy after successful resection. In: Salmon, SE, editor. Adjuvant therapy of cancer VII. Philadelphia: JB Lippincott; 1993. p. 261-9.
166. Ajani JM, Mansfield PF, Dumas P, et al. All chemotherapy preoperatively with cisplatin, 5-FU and intron, in patients with potentially resectable gastric carcinoma[Abstract]. Proceedings of the American Society of Clinical Oncology 1996:15:208.
167. Kelsen D, Karpeh M, Schwartz G, et al. Neoadjuvant and postoperative chemotherapy for high-risk gastric cancer [Abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:195.
168. Alexander HR, Grem JL, Hamilton JM, et al. Thymidylate synthase protein exprès-sion: association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. Cancer Journal 1995; 1:49-54.
169. Kang Y-K, Choi D-W, Im Y-H, et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer [Abstract]. Proceedings of the American Society of Clinical Oncology 1996:15:215.
170. Mantell BS. Radiotherapy for dysphagia due to gastric carcinoma. Br J Surg 1982:69:69-70.
171. Tsukiyama I, Akine Y, Kajiura Y Radiation therapy for advanced gastric cancer. Int J Radiât Oncol Biol Phys 1988;15:123-7.
172. Lawrence TS, Tesser RJ, Ten Haken RK. An application of dose-volume histograms to the treatment of intrahepatic malignancies with radiation therapy. Int J Radiât Oncol Biol Phys 1990:19:1041-7.
173. Shank B, LoSasso T, Brewster L, et al. Three dimensional treatment planning for postoperative treatment of rectal carcinoma. Int J Radiât Oncol Biol Phys 1991:21:253-65.
174. Tait D, Nahum A, Southall C, Chow M, Yarnold JR. Benefits expected from simple conformai radiotherapy in the treatment of pelvic tumors. Radiother Oncol 1988:13:23-30.
175. Ten Haken RK, Lawrence TS, McShan DL, Tesser RJ, Fraas BA, Lichter AS. Technical consideration in the use of 3-D beam arrangements in the abdomen. Int J Radiât Oncol Biol Phys 1991;22:19-28.
176. Lichter AS, Lawrence TS. Recent advances in radiation oncology. N Engl J Med 1995;332:371-9.
177. Abe M, Takahashi M, Ono K, Tobe T, Inamoto T. Japan gastric trials in intraoperative radiation therapy. Int J Radiât Oncol Biol Phys 1988:15:1431-3.
178. Abe M, Shibamoto, Y, Takahashi M, Manaba T, Tobe T, Inamoto T. Intraoperative radiotherapy in carcinoma of the stomach and pancreas. World J Surg 1987; 11:459-64.
179. Chen G, Song S: Evaluation of intraoperative radiotherapy for gastric carcinoma: analysis of 247 patients. In: Abe M, Takahashi M, editors. Intraoperative radiation therapy. New York: Pergamon Press; 1991. p. 190-1.
180. ! 80. Gérard JP, Sentenac I, Gilly F, et al. Intraoperative radiotherapy (IORT) for carcinoma of the stomach with the Lyon intraoperative system (LIS): a series of 27 patients. In: Abe M, Takahashi M. editors. Intraoperative radiation therapy. New York: Pergamon Press; 1991. p. 195-6.
181. Guillemin F. Malissard L, Aletti P, Bey P, Verhaeghe JL, Godfrin PY. Intraoperative radiation therapy for carcinoma of the stomach: a five year experience: pilot study. In: Abe M, Takahashi M, editors. Intraoperative radiation therapy. New York: Pergamon Press; 1991. p. 199-200.
182. Jiang YY. Liu JQ, Chen XG, Song SB. The basic and clinical studies of intraoperative radiation therapy for gastric cancer. In: Abe M, Takahashi M, editors. Intraoperative radiation therapy. New York: Pergamon Press; 1991. p. 187-9.
183. Kirn MS. Kim SK, Song SK, Kwun KB, Kim HD, Chung MK. Intraoperative radiation therapy in Korea. In: Abe M, Takahashi M, editors. Intraoperative radiation therapy. New York: Pergamon Press; 1991. p. 197-8.
184. Sindelar WF. Intraoperative radiotherapy in carcinoma of the stomach and pancreas. Recent Results Cancer Res 1988;! 10:226-43.
185. Calvo SA, Aristu JJ, Azinovic I, et al. Intraoperative and external radiotherapy in resected gastric cancer: updated report of a phase II trial. Int J Radiât Oncol Biol Phys 1992;24:729-36.
186. Dulce MC, Kaiser J, Boese-Landgraf J. Experiences with intraoperative radiotherapy in gastric carcinoma (Berlin method). Strahlenther Oncol 1991; 167:581-90.
187. Ogata T, Araki K, Matsuura K, et al. A 10-year experience of intraoperative radiotherapy for gastric carcinoma and a new surgical method of creating a wider irradiation field for cases of total gastrectomy patients. Int J Radiât Oncol Biol Phys 1995;32:341-7.
188. Caudry M, Escarmant P, Maire JP, Demeaux H, Guichard F, Azaloux H. Radiotherapy of gastric cancer with a three field combination: feasibility, tolerance and survival. Int J Radiât Oncol Biol Phys 1987:13:1821-7.
189. Gunderson LL, Hoskins B, Cohen AM, Kaufman S, Wood W, Carey R. Combined modality treatment of gastric cancer. Int J Radiât Oncol Biol Phys 1983:9:965-75.
190. Slot A, Meerwaldt JH, van Putten WL, Treuniet-Donker AD. Adjuvant postoperative radiotherapy for gastric carcinoma with poor prognostic signs. Radiother Oncol 1989; 16:269-74.
191. Régine WF, Mohiuddin M. Impact of adjuvant therapy on locally advanced adenocarcinoma of the stomach. Int J Radiât Oncol Biol Phys 1992;24:921-7.
192. Dent DM, Werner ID, Novis B, Chevreton P, Brice P. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979;44:385-91.
193. Allum WH, Hallissey MT, Ward LC, Hockey MS. A controlled, prospective, randomized trial of adjuvant chemotherapy or radiotherapy in resectable gastric interim report. British Stomach Cancer Group. Br J Cancer 1989;60:739-44.
194. Moertel.CG, Childs DS, Fallen JR. Combined 5-fluorouracil and radiation
195. Gastrointestinal Tumor Study Group. A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 1982;49:1771-7.
196. O'Brien MER, Cunningham D. The role of chemotherapy for metastatic gastric cancer. J Inf Chemoth 1995;5:112-6.
197. Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993; 19:29-44.
198. Schipper DL, Wagener DJT. Chemotherapy of gastric cancer. Anticancer Drugs 1996;7:137-49.
199. Fink U, Sendler A. Möglichkeiten der Chemotherapie beim fortgeschrittenen Magencarcinom. In: Schmid L, Wilmanns W, editors. Aktuelle Onkologie 1995;87:43-53.
200. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluoruracil, epidoxorubicin and methotrexate (FEMTx) with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
201. Murad AM, Santiago FF, Petroianu A, Rocha PRS, Rodrigues MAG, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
202. Glimelius B, Hoffman K, Haglund J, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-90.
203. Scheithauer W, Kornek G, Zeh B. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer. Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Köln, Germany, 1995, p. 68.
204. Wieland C, Hymmen V. Megavoltage therapy for malignant gastric tumors. Strahlenther Onkol 1970;140:20-6.
205. Nordman E. Value of megavolt therapy in gastric carcinoma. Bull Cancer 1976;63:217-22.
206. Haas CD, Mansfield CM, Leichman LP, Considine B, Bukowski RM. Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study. Cancer Treat Rep 1983;67:421-4.
207. O'Connel MJ, Gunderson LL, Moertel CG, Kvols LK. A pilot study to determine clinical tolerability of intensive combined modality therapy for locally unresectable gastric cancer. Int J Radiât Oncol Biol Phys 1985;11:1827-31.
208. Schein P. A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 1982;49:1771-7.
209. Childs DS, Moertel CG, Holbrood MA. Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-fluorouracil and radiation. Am J Roentgenol Radium Ther Nucl Med 1968;102:541-4.
210. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA. Combined 5-FU and supervoltage radiation therapy of locally unresectable GI cancer. Lancet 1969;2:865-7.
211. Falkson G, Falkson HC. Fluorouracil and radiotherapy in gastrointestinal cancer. Lancet 1969;2:1252-3.
212. Falkson G, van Eden EB. A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bischloroethyl nitrosourea plus radiotherapy in stomach cancer. Med Pediatr Oncol 1976;2:lll-7.
213. Hazel JJ, Thirlwell MP, Huggins M. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 1981;32:164-5.
214. Klaassen DJ, Macintyre JM, Cotton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-FU alone with radiation plus concurrent and maintenance 5-FU: an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-8.
215. The Gastrointestinal Tumor Study Group (GITSG). The concept of locally advanced gastric cancer: effect of treatment on outcome. Cancer 1990;66:2324-30.
216. Siewert JR. Breitner: Chirurgische Operationslehre, Bd TV Chirurgie des Abdomens 2. Ösophagus, Magen, Duodenum. München: Urban & Schwarzenberg; 1989.
217. Siewert JR, Stein HJ, Böttcher K. Lymphadenektomie bei Tumoren des oberen Gastrointestinaltraktes. Chirurg 1996;67:977-88.